These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3143585)

  • 21. Comparative in vitro activity of the two new 4-quinolones S-25930 and S-25932 against gram-positive bacteria isolated from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):681-3. PubMed ID: 3143584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activities of tosufloxacin, temafloxacin, and A-56620 against pathogens of diarrhea.
    Bryan JP; Waters C; Sheffield J; Krieg RE; Perine PL; Wagner K
    Antimicrob Agents Chemother; 1990 Feb; 34(2):368-70. PubMed ID: 2327784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative activity of three new fluoroquinolones.
    Coll R; Esteve M; Moros M; Parés J; Xicota MA
    Chemioterapia; 1987 Jun; 6(2 Suppl):152-3. PubMed ID: 3509374
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1990; 36(5):365-72. PubMed ID: 2209169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in vitro activity of lomefloxacin (SC 47111 or NY-198) against fresh clinical bacterial isolates.
    Wright DN; Saxon B; Matsen JM
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):7S-11S. PubMed ID: 2791501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibacterial activity of the new quinolone CI-960 (PD 127391) against clinical isolates at a major tertiary care center in Saudi Arabia.
    Qadri SM; Abo-Askar H; Ueno Y
    Chemotherapy; 1992; 38(2):92-8. PubMed ID: 1317281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro comparison of E4868, a new trifluoroquinolone, with ciprofloxacin and temafloxacin tested against 5192 recent clinical isolates from five medical centers.
    Murray PR; Jones RN; Washington JA; Gerlach EH; Allen SD
    Diagn Microbiol Infect Dis; 1993; 17(4):307-11. PubMed ID: 8112046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lomefloxacin (SC 47111 or NY-198), a new difluorinated quinolone: comparison of the in vitro activity with other broad spectrum antimicrobials against Enterobacteriaceae, Acinetobacter spp, Aeromonas spp, and Pseudomonas aeruginosa.
    Aldridge KE; Henderberg A; Sanders CV
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):1S-6S. PubMed ID: 2507219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Drugs Exp Clin Res; 1992; 18(8):311-7. PubMed ID: 1338041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
    Floyd-Reising SA; Kelley SG; Hindler JA; Young LS
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):301-6. PubMed ID: 3472704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro activity of three fluoroquinolones, cefotaxime and clindamycin against staphylococci.
    Schumacher-Perdreau F; Peters G
    Zentralbl Bakteriol; 1995 Oct; 282(4):389-93. PubMed ID: 9810661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-vitro activity of tosufloxacin, a new quinolone antibacterial agent.
    Cooper MA; Andrews JM; Wise R
    J Antimicrob Chemother; 1992 Jun; 29(6):639-47. PubMed ID: 1506348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
    Rolston KV; Frisbee-Hume S; LeBlanc BM; Streeter H; Ho DH
    Diagn Microbiol Infect Dis; 2002 Oct; 44(2):187-94. PubMed ID: 12458127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-vitro activity of temafloxacin for gram-positive pathogens.
    Bille J; Glauser MP
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():9-14. PubMed ID: 1664835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.
    Thomson KS; Sanders CC; Hayden ME
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2329-34. PubMed ID: 1804005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the bactericidal activity of temafloxacin.
    Jacobs MR
    Am J Med; 1991 Dec; 91(6A):31S-34S. PubMed ID: 1662893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin.
    Nye K; Shi YG; Andrews JM; Ashby JP; Wise R
    J Antimicrob Chemother; 1989 Sep; 24(3):415-24. PubMed ID: 2808194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.